Gossamer Bio (GOSS) Expected to Announce Earnings on Tuesday

Gossamer Bio (NASDAQ:GOSS) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $7.02 million for the quarter.

Gossamer Bio Price Performance

Shares of GOSS opened at $1.30 on Tuesday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The company has a 50 day moving average price of $1.03 and a 200-day moving average price of $0.93. Gossamer Bio has a fifty-two week low of $0.50 and a fifty-two week high of $1.60. The stock has a market capitalization of $294.58 million, a PE ratio of -4.06 and a beta of 1.81.

Institutional Investors Weigh In On Gossamer Bio

An institutional investor recently raised its position in Gossamer Bio stock. Bank of America Corp DE raised its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 107.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 84,788 shares of the company’s stock after purchasing an additional 43,866 shares during the period. Bank of America Corp DE’s holdings in Gossamer Bio were worth $77,000 at the end of the most recent quarter. Institutional investors own 81.23% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Thursday, January 30th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Gossamer Bio presently has an average rating of “Buy” and a consensus price target of $9.20.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.